Allogene Therapeutics

Founded in San Francisco, Allogene Therapeutics is a clinical-stage biotechnology company dedicated to pioneering allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The company's core mission is to revolutionize cancer treatment by developing "off-the-shelf" CAR T products that can be readily available to patients, bypassing the limitations of autologous CAR T therapies. Allogene's vision is to unlock the fourth great wave in cancer treatment, making advanced therapies more accessible and effective.

Notable figures affiliated with Allogene Therapeutics include Dr. Zachary Roberts, who plays a significant role in advancing the company's research and development efforts. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid growth and innovation. Key achievements include the successful development of its allogeneic cell therapy platform and significant progress in clinical trials. Overall, Allogene Therapeutics is making a substantial impact on the future of cancer treatment by offering groundbreaking solutions that promise to improve patient outcomes.